CompBrief BY VELARION

Companies AtriCure, Inc.

AtriCure CEO salary & total pay, FY2025: $9.2M

AtriCure (ATRC) CEO salary, fiscal 2025: Michael Carrel was paid a salary of $828,439 and $9,217,620 in total compensation. Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me AtriCure, Inc.’s executive pay brief as a PDF

You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

Also free: The Pay Desk, the weekly executive pay briefing.

Michael Carrel's complete compensation dossier

A PDF and a CSV sent to your email: Michael Carrel's pay in every fiscal year AtriCure, Inc. reported it, line by line, with Michael Carrel's equity grants and AtriCure, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.

One-time report. No refunds.

See an example →
CEO total pay$9,217,620CEO Michael Carrel · source
Say-on-pay support95.71%Latest vote · source
CEO vs. named peers57th pct.Of 15 peer CEOs
CEO pay ratio64:1To the median employee · source

CEO pay, last three years

  • $8,749,289FY2023
  • $11,070,400FY2024
  • $9,217,620FY2025

CEO total pay was $9,217,620 in fiscal 2025, down from $11,070,400 in fiscal 2024.

FY2025: salary $828,439 · bonus $0 · stock awards $7,203,478 · option awards $0

Executives and directors

Frequently asked questions

Who was the highest-paid executive at AtriCure, Inc. in fiscal 2025?
As disclosed, Michael Carrel (President and Chief Executive Officer) was the highest-paid executive at AtriCure, Inc. in fiscal 2025, with total compensation of $9,217,620.
How does AtriCure, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Michael Carrel's total compensation ranked at the 57th percentile of AtriCure, Inc.'s disclosed peer group.
What is AtriCure, Inc.'s CEO-to-median employee pay ratio?
As disclosed, AtriCure, Inc.'s CEO-to-median employee pay ratio was 64:1.
How did shareholders vote on AtriCure, Inc.'s executive compensation?
As disclosed, 95.71% of shareholders supported AtriCure, Inc.'s executive compensation in the latest say-on-pay vote.
How much does AtriCure, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, AtriCure, Inc. reported total board compensation of $2,002,436 for fiscal 2025.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Michael Carrel$828,439$0$7,203,478$0$1,171,703$0$14,000$9,217,620
President and Chief Executive Officer
Douglas Seith572,22002,697,1730659,390021,2003,949,983
Chief Operating Officer
Angela Wirick523,36602,535,3450504,452011,7503,574,913
Chief Financial Officer
Salvatore Privitera447,76501,888,0030364,218014,0002,713,986
Chief Technical Officer
Justin Noznesky452,11201,618,2640367,754011,7502,449,880
Chief Marketing and Strategy Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2025 totalFY2024 totalFY2023 totalΔ FY2024→2025
Michael Carrel$9,217,620$11,070,400$8,749,289↓ −1,852,780
Douglas Seith3,949,9834,116,2193,499,842↓ −166,236
Angela Wirick3,574,9133,289,5912,921,357↑ +285,322
Salvatore Privitera2,713,986—2,127,121—
Justin Noznesky2,449,8802,273,373—↑ +176,507

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

Our compensation philosophy is rooted in a pay for performance approach while also considering internal equity and fairness. This approach is designed to strongly link executive officer compensation to our performance. Executive incentive compensation is tied to measurable results intended to create long-term value for our stockholders.

CEO STI target (% of salary)105%
CEO LTI target (% of salary)—
Independent consultantKorn Ferry
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingTrue
Equity grants and outstanding awards

Grants of plan-based awards — fiscal year 2025

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Michael CarrelRSU2025-03-01——50,335—$1,949,978
Justin NozneskyRSU2025-03-01——19,359—749,968
Salvatore PriviteraRSU2025-03-01——22,586—874,982
Douglas SeithRSU2025-03-01——32,266—1,249,985
Justin NozneskyPSU2025-03-019,67919,359—38,718865,934
Salvatore PriviteraPSU2025-03-0111,29322,586—45,1721,010,266
Michael CarrelPSU2025-03-0158,724117,449—234,8985,253,500
Douglas SeithPSU2025-03-0116,13432,266—64,5321,443,252
Angela WirickPSU2025-03-0115,16630,330—60,6601,356,661
Angela WirickRSU2025-03-01——30,330—1,174,984

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Michael Carrel$1,949,978$5,253,500$072.9%
Justin Noznesky749,968865,934053.6%
Salvatore Privitera874,9821,010,266053.6%
Douglas Seith1,249,9851,443,252053.6%
Angela Wirick1,174,9841,356,661053.6%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

Outstanding equity awards at fiscal year-end 2025

ExecutiveAwardExercisableShares unvestedExercise priceMarket value unvested
Angela WirickRSU—8,159—$322,770
Angela WirickPSU—23,101—913,876
Angela WirickRSU—20,672—817,784
Angela WirickPSU—31,008—1,226,676
Angela WirickRSU—30,330—1,199,855
Angela WirickPSU—30,330—1,199,855
Douglas SeithRSU—9,018—356,752
Douglas SeithPSU—25,532—1,010,046
Douglas SeithRSU—25,266—999,523
Douglas SeithPSU—37,899—1,499,284
Douglas SeithRSU—32,266—1,276,443
Douglas SeithPSU—32,266—1,276,443
Justin NozneskyRSU—5,368—212,358
Justin NozneskyPSU—19,294—763,271
Justin NozneskyPSU—15,198—601,233
Justin NozneskyRSU—12,862—508,821
Justin NozneskyRSU—19,359—765,842
Justin NozneskyPSU—19,359—765,842
Michael CarrelRSU—15,331—606,494
Michael CarrelPSU—101,280—4,006,637
Michael CarrelRSU—33,902—1,341,163
Michael CarrelPSU—118,660—4,694,190
Michael CarrelRSU—50,335—1,991,253
Michael CarrelPSU—117,449—4,646,282
Salvatore PriviteraPSU—15,198—601,233
Salvatore PriviteraRSU—12,862—508,821
Salvatore PriviteraRSU—22,586—893,502
Salvatore PriviteraPSU—22,586—893,502
Salvatore PriviteraRSU—5,368—212,358
Salvatore PriviteraPSU—19,294—763,271
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Robert S. WhiteIndependent · Board Chair · Nominating and Corporate Governance · Strategy$112,500$174,992$0$0$0$287,492
Regina E. GrovesIndependent · Audit · Compliance, Quality & Risk (Chair) · Strategy82,500174,992000257,492
Sven A. WehrweinIndependent · Audit (Chair) · Compliance, Quality & Risk77,500174,992000252,492
Karen N. PrangeIndependent · Compensation (Chair) · Nominating and Corporate Governance70,000174,992000244,992
B. Kristine JohnsonIndependent · Compensation · Strategy (Chair)67,500174,992000242,492
Deborah H. TelmanIndependent · Compensation · Nominating and Corporate Governance (Chair)67,500174,992000242,492
Shlomo NachmanIndependent · Compliance, Quality & Risk · Strategy65,000174,992000239,992
Maggie YuenIndependent · Audit60,000174,992000234,992
Michael H. CarrelEmployee director000—00

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer$175,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline3x annual cash retainer

Total cost of the board

ComponentFY2025
Cash retainers and fees$602,500
Equity awards (grant-date value)$1,399,936
All other compensation$0
Total cost of the board$2,002,436

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names AtriCure as a peer

Companies that benchmark against ATRC

29 companies name ATRC as a compensation peer

Each company listed discloses ATRC in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ATRC in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Disclosed peer group — fiscal year 2025

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

Peer reciprocity

The companies AtriCure, Inc. names as compensation peers that name it back in their own disclosed peer groups.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Insulet Corporation2025Ashley McEvoy$729,808$12,958,850$2,999,913$2,031,562$18,858,968
2Haemonetics Corporation2026Christopher Simon1,100,0087,561,9871,504,9681,834,25012,044,701
3Glaukos Corporation2025Thomas Burns850,0007,649,9473,527,497012,034,087
4Nevro Corp2023Kevin Thornal515,62510,080,1730402,75011,453,548
5iRhythm Holdings, Inc.2025Quentin Blackford700,0038,919,45701,350,00011,003,163
6Alphatec Holdings, Inc.2025Patrick Miles762,0008,859,6500600,00010,260,507
7AtriCure, Inc.2025Michael Carrel828,4397,203,47801,171,7039,217,620
8Axogen, Inc.2025Michael Dale775,8657,342,8950906,1339,047,454
9LivaNova Plc2025Vladimir Makatsaria956,1154,303,0921,374,9991,287,6568,047,217
10Inspire Medical Systems, Inc.2025Timothy Herbert750,5725,999,6550961,5577,711,784
11Staar Surgical Company2025Stephen Farrell580,0006,836,000007,522,385
12Artivion, Inc.2025J. Patrick Mackin835,1455,006,9900991,3686,883,108
13Tandem Diabetes Care, Inc.2025John Sheridan790,5835,367,7960674,0906,858,503
14Tactile Systems Technology, Inc.2025Sheri Dodd675,0002,019,9780737,4383,466,916
15Penumbra, Inc.2025Adam Elsesser850,000000851,621
—Inari Medical, Inc.——————not in coverage universe

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
AtriCure, Inc.not disclosedPSU 50 · Restricted Stock 50NoKorn Ferry
Alphatec Holdings, Inc.157%PSU 50 · RSU 50NoCompensia
Artivion, Inc.118.7%PSU 50 · RSU 50NoWillis Towers Watson
Axogen, Inc.116.79%PSU 50 · RSU 50NoAon
Glaukos Corporationnot disclosedRSU 50 · PRSU 50NoFrederic W. Cook & Co., Inc.
Haemonetics Corporation133.4%PSU 60 · RSU 20 · Options 20Yes — Relative Total Shareholder Return (rTSR)Pearl Meyer & Partners, LLC
Inari Medical, Inc.not disclosednot disclosednot disclosednot disclosed
Inspire Medical Systems, Inc.111.4%PSU 50 · RSU 50NoAon
Insulet Corporation195.8%PSU 60 · RSU 20 · Options 20NoPearl Meyer & Partners, LLC
iRhythm Holdings, Inc.173%RSU 50 · PSU 50Yes — Relative TSRAon and Mercer
LivaNova Plc122.4%PSU 50 · RSU 25 · Options 25NoPearl Meyer
Nevro Corp53.7%RSU 50 · PSU 50NoAon
Penumbra, Inc.not disclosednot disclosedNoCompensia
Staar Surgical Company135%RSU 50 · PSU 50NoSemler Brossy
Tactile Systems Technology, Inc.115%PSU 50 · RSU 50NoAon Consulting, Inc.
Tandem Diabetes Care, Inc.87%PSU 50 · RSU 50Yes — TSR performance compared to the Russell 3000 index in the three-year period between 2025 and 2027WTW

Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20262026-05-1840,373,4271,745,37962,34295.71%Passed
20252025-05-1932,367,7518,655,946120,98578.67%Passed
20242024-05-1335,640,2386,475,86098,23984.43%Passed
20232023-05-2533,710,0166,620,61163,64583.45%Passed
20222022-05-2539,728,8641,415,11958,19096.42%Passed
20212021-05-2039,361,5461,793,10417,03395.6%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20262026-05-1895.71%a
20252025-05-1978.67%b
20242024-05-1384.43%c

a. Approved under the standard stated in the filing — “abstention has the same effect as a vote "AGAINST".”.

b. Approved under the standard stated in the filing — “you "ABSTAIN", your abstention has the same effect as a vote "AGAINST".”.

c. Approved under the standard stated in the filing — “you "ABSTAIN", your abstention has the same effect as a vote "AGAINST".”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

CEO pay ratio

Ratio (CEO : median employee)64 : 1
CEO total compensation$9,217,620
Median employee compensation$144,309
Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Vinayak DoraiswamyChief Scientific Officer2026-05-15D5,000$28$140,650CommonForm 4 ↗
Robert S. WhiteDirector2026-05-18A6,14400CommonForm 4 ↗
Sven A. WehrweinDirector2026-05-18A6,14400CommonForm 4 ↗
Regina E. GrovesDirector2026-05-18A6,14400CommonForm 4 ↗
Shlomo NachmanDirector2026-05-18A6,14400CommonForm 4 ↗
Maggie YuenDirector2026-05-18A6,14400CommonForm 4 ↗
Deborah H. TelmanDirector2026-05-18A6,14400CommonForm 4 ↗
Karen N. PrangeDirector2026-05-18A6,14400CommonForm 4 ↗
B. Kristine JohnsonDirector2026-05-18A6,14400CommonForm 4 ↗
Karen N. PrangeDirector2026-05-20D3,0002985,950CommonForm 4 ↗
Salvatore PriviteraChief Technical Officer2026-06-30A6362415,124CommonForm 4 ↗
Karl S. DahlquistChief Legal Officer2026-06-30A6362415,124CommonForm 4 ↗
Vinayak DoraiswamyChief Scientific Officer2026-06-30A6362415,124CommonForm 4 ↗
Michael H. CarrelDirector2026-06-30A6362415,124CommonForm 4 ↗
Douglas SeithChief Operating Officer2026-06-30A5272412,532CommonForm 4 ↗
Sven A. WehrweinDirector2026-07-28D25,00000Derivative, Class A CommonForm 4 ↗
Sven A. WehrweinDirector2026-07-28D25,00038946,000CommonForm 4 ↗
Sven A. WehrweinDirector2026-07-28A25,00020498,750CommonForm 4 ↗
Vinayak DoraiswamyChief Scientific Officer2026-07-28D6,00039233,280CommonForm 4 ↗
Justin NozneskyChief Mktg & Strategy Officer2026-07-29D6,18239239,862CommonForm 4 ↗
Michael H. CarrelDirector2026-07-30D4,00000CommonForm 4 ↗
Michael H. CarrelDirector2026-07-30D70000CommonForm 4 ↗
Maggie YuenDirector2026-08-05D3,50038134,470CommonForm 4 ↗
Karen N. PrangeDirector2026-08-05D3,56439138,283CommonForm 4 ↗
Karl S. DahlquistChief Legal Officer2026-08-24D9,37049458,099CommonForm 4 ↗
Salvatore PriviteraChief Technical Officer2026-09-02D7,76353407,558CommonForm 4 ↗
Salvatore PriviteraChief Technical Officer2026-09-08D3,65755201,135CommonForm 4 ↗
Regina E. GrovesDirector2026-09-11D5,31354288,071CommonForm 4 ↗
Salvatore PriviteraChief Technical Officer2026-09-23D4,51960271,140CommonForm 4 ↗
Salvatore PriviteraChief Technical Officer2026-11-04D8,40465546,260CommonForm 4 ↗
B. Kristine JohnsonDirector2026-11-06D2,45258143,393CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

Sources (86 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, Michael Carrel. DEF 14A, filed 2026-04-06. Section “Summary Compensation Table” · page 47. As printed: 9,217,620. View filing ↗
  • Section 01, Douglas Seith. DEF 14A, filed 2026-04-06. Section “Summary Compensation Table” · page 47. As printed: 3,949,983. View filing ↗
  • Section 01, Angela Wirick. DEF 14A, filed 2026-04-06. Section “Summary Compensation Table” · page 47. As printed: 3,574,913. View filing ↗
  • Section 01, Salvatore Privitera. DEF 14A, filed 2026-04-06. Section “Summary Compensation Table” · page 47. As printed: 2,713,986. View filing ↗
  • Section 01, Justin Noznesky. DEF 14A, filed 2026-04-06. Section “Summary Compensation Table” · page 47. As printed: 2,449,880. View filing ↗
  • Section 03, Michael Carrel RSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Justin Noznesky RSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Salvatore Privitera RSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Douglas Seith RSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Justin Noznesky PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Salvatore Privitera PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Michael Carrel PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Douglas Seith PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Angela Wirick PSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 03, Angela Wirick RSU. DEF 14A, filed 2026-04-06. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
  • Section 07, pay ratio. DEF 14A, filed 2026-04-06. Section “CEO Pay Ratio”. As printed: 64 : 1. View filing ↗
  • Section 08, Robert S. White. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 287,492. View filing ↗
  • Section 08, Regina E. Groves. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 257,492. View filing ↗
  • Section 08, Sven A. Wehrwein. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 252,492. View filing ↗
  • Section 08, Karen N. Prange. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 244,992. View filing ↗
  • Section 08, B. Kristine Johnson. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 242,492. View filing ↗
  • Section 08, Deborah H. Telman. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 242,492. View filing ↗
  • Section 08, Shlomo Nachman. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 239,992. View filing ↗
  • Section 08, Maggie Yuen. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 234,992. View filing ↗
  • Section 08, Michael H. Carrel. DEF 14A, filed 2026-04-06. Section “Director Compensation”. As printed: 0. View filing ↗
  • Section 02, Vinayak Doraiswamy 2026-05-15. Form 4, filed 2026-05-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Robert S. White 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Sven A. Wehrwein 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Regina E. Groves 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Shlomo Nachman 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Maggie Yuen 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Deborah H. Telman 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Karen N. Prange 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, B. Kristine Johnson 2026-05-18. Form 4, filed 2026-05-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Karen N. Prange 2026-05-20. Form 4, filed 2026-05-22. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Salvatore Privitera 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Karl S. Dahlquist 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Vinayak Doraiswamy 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael H. Carrel 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Douglas Seith 2026-06-30. Form 4, filed 2026-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Sven A. Wehrwein 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Sven A. Wehrwein 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Sven A. Wehrwein 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Vinayak Doraiswamy 2026-07-28. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Justin Noznesky 2026-07-29. Form 4, filed 2026-07-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael H. Carrel 2026-07-30. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Michael H. Carrel 2026-07-30. Form 4, filed 2026-08-03. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Maggie Yuen 2026-08-05. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Karen N. Prange 2026-08-05. Form 4, filed 2026-08-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Karl S. Dahlquist 2026-08-24. Form 4, filed 2026-08-26. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Salvatore Privitera 2026-09-02. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Salvatore Privitera 2026-09-08. Form 4, filed 2026-09-10. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Regina E. Groves 2026-09-11. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Salvatore Privitera 2026-09-23. Form 4, filed 2026-09-24. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Salvatore Privitera 2026-11-04. Form 4, filed 2026-11-05. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, B. Kristine Johnson 2026-11-06. Form 4, filed 2026-11-10. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 06, 2026 vote. Form 8-K, filed 2026-05-19. Item 5.07 · say-on-pay result. As reported: 95.71% (votes for as printed: 40,373,427). View filing ↗
  • Section 06, 2025 vote. Form 8-K, filed 2025-05-20. Item 5.07 · say-on-pay result. As reported: 78.67% (votes for as printed: 32,367,751). View filing ↗
  • Section 06, 2024 vote. Form 8-K, filed 2024-05-14. Item 5.07 · say-on-pay result. As reported: 84.43% (votes for as printed: 35,640,238). View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
  • Section 09b board cost (computed). Computed. Cash 602,500 + equity 1,399,936 + all other 0 = 2,002,436, summed across the director compensation table rows.
  • Insulet Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Insulet Corporation's own proxy. As printed: 18,858,968. View filing ↗
  • Haemonetics Corporation, Section 10b CEO total. DEF 14A, filed 2026-06-09. CEO total compensation as printed in Haemonetics Corporation's own proxy. As printed: 12,044,701. View filing ↗
  • Glaukos Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-16. CEO total compensation as printed in Glaukos Corporation's own proxy. As printed: 12,034,087. View filing ↗
  • Nevro Corp, Section 10b CEO total. DEF 14A, filed 2024-04-12. CEO total compensation as printed in Nevro Corp's own proxy. As printed: 11,453,548. View filing ↗
  • iRhythm Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in iRhythm Holdings, Inc.'s own proxy. As printed: 11,003,163. View filing ↗
  • Alphatec Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Alphatec Holdings, Inc.'s own proxy. As printed: 10,260,507. View filing ↗
  • AtriCure, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in AtriCure, Inc.'s own proxy. As printed: 9,217,620. View filing ↗
  • Axogen, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Axogen, Inc.'s own proxy. As printed: 9,047,454. View filing ↗
  • LivaNova Plc, Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in LivaNova Plc's own proxy. As printed: 8,047,217. View filing ↗
  • Inspire Medical Systems, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-20. CEO total compensation as printed in Inspire Medical Systems, Inc.'s own proxy. As printed: 7,711,784. View filing ↗
  • Staar Surgical Company, Section 10b CEO total. DEF 14A, filed 2026-05-04. CEO total compensation as printed in Staar Surgical Company's own proxy. As printed: 7,522,385. View filing ↗
  • Artivion, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-01. CEO total compensation as printed in Artivion, Inc.'s own proxy. As printed: 6,883,108. View filing ↗
  • Tandem Diabetes Care, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Tandem Diabetes Care, Inc.'s own proxy. As printed: 6,858,503. View filing ↗
  • Tactile Systems Technology, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-25. CEO total compensation as printed in Tactile Systems Technology, Inc.'s own proxy. As printed: 3,466,916. View filing ↗
  • Penumbra, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Penumbra, Inc.'s own proxy. As printed: 851,621. View filing ↗
  • Section 10a, Tandem Diabetes Care, Inc. reciprocity. DEF 14A. Tandem Diabetes Care, Inc. names AtriCure, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
  • Section 10a, iRhythm Holdings, Inc. reciprocity. DEF 14A. iRhythm Holdings, Inc. names AtriCure, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
  • Section 10a, STAAR Surgical Company reciprocity. DEF 14A. STAAR Surgical Company names AtriCure, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
  • Section 10a, Tactile Systems Technology, Inc. reciprocity. DEF 14A. Tactile Systems Technology, Inc. names AtriCure, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
  • Section 10a, Inspire Medical Systems, Inc. reciprocity. DEF 14A. Inspire Medical Systems, Inc. names AtriCure, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
  • Section 10a, Axogen, Inc. reciprocity. DEF 14A. Axogen, Inc. names AtriCure, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
  • Section 10a, Artivion, Inc. reciprocity. DEF 14A. Artivion, Inc. names AtriCure, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
  • Section 10a, Alphatec Holdings, Inc. reciprocity. DEF 14A. Alphatec Holdings, Inc. names AtriCure, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
  • Section 10a, Nevro Corp reciprocity. DEF 14A. Nevro Corp names AtriCure, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
Get the full report — $299